You will not be allowed to compare more than 4 products at a time
View compare
GLP-1 information
Understand how GLP-1 treatments work
Learn how GLP-1 medicines can support weight loss, who may be eligible, what results may look like over time, and which GLP-1 treatments are available through NuVue.
Clinician reviewed
Mounjaro & Wegovy available
Discreet delivery
At a glance
What is GLP-1?
GLP-1 is a natural hormone released after eating that helps regulate appetite, blood sugar and how quickly your stomach empties.
Which GLP-1s are available through NuVue?
Mounjaro and Wegovy are the GLP-1-based treatments currently available through NuVue.
Who may be eligible?
Adults with obesity, or adults who are overweight with a weight-related health condition, may be eligible subject to clinician review.
How GLP-1 works
How GLP-1 treatments may help you lose weight
GLP-1 is a natural hormone released in your gut after eating. GLP-1 medicines mimic or enhance these effects to support appetite regulation and weight management.
What GLP-1 does in the body
- Stimulates insulin release to help lower blood sugar
- Suppresses glucagon, which raises blood sugar
- Slows gastric emptying so you may feel fuller for longer
- Acts on appetite pathways in the brain to help reduce hunger
Why this matters for weight loss
By helping you feel fuller sooner and for longer, GLP-1 treatments can reduce appetite, support smaller portions and make it easier to stay consistent with a reduced-calorie plan over time.
Eligibility
Who may be eligible?
Eligibility is always subject to clinician review, but GLP-1 treatment may be considered if you meet one of the following criteria.
BMI 30 or above
You may be eligible if you have a body mass index (BMI) of 30 or more, which falls within the obesity category.
BMI 27 or above with a related condition
You may also be eligible if your BMI is 27 or higher and you have at least one weight-related health condition, such as high blood pressure or type 2 diabetes.
NHS access
Can I get this on the NHS?
NHS access is different from private prescribing. Private eligibility may be broader than NHS eligibility, depending on the treatment and your medical history.
NHS guidance
Wegovy has been recommended by NICE for some adults on the NHS in England alongside a reduced-calorie diet and increased physical activity. In practice, NHS access is typically more restricted and often depends on BMI thresholds, comorbidities and local specialist service pathways.
Private access through NuVue
Private providers like NuVue may assess eligibility under the licensed use of the medicine and your individual medical circumstances. This can include adults with a BMI of 27 or above with a weight-related condition, or a BMI of 30 or above without additional conditions, subject to clinician review.
NHS availability can vary by pathway and region. A private consultation does not guarantee treatment, as suitability still needs to be assessed safely by a prescriber.
Results timeline
How quickly will I see results?
Everyone responds differently. Some people notice reduced appetite within the first 1 to 2 weeks, while for others it can take longer. The aim is steady, sustainable weight loss over time.
Weeks 1–2
Early appetite changes
You may begin to notice reduced hunger, smaller portions or feeling fuller for longer.
Weeks 3–8
Building consistency
As your body adjusts, the focus is usually on consistency, hydration, routine and sustainable habits.
Longer term
Steady progress
Results typically build over time, particularly when medication is paired with lifestyle changes and ongoing support.
Efficacy & outcomes
What do the outcomes look like?
Published studies have shown meaningful improvements in body weight and metabolic markers with GLP-1-based treatments, particularly tirzepatide and semaglutide when used alongside lifestyle support.
15–22.5%
Average body weight reduction
Weight loss studies have reported average reductions in this range, with tirzepatide showing stronger average reductions than GLP-1 only treatments in some trials.
Up to 2.6
HbA1c point reduction
Diabetes studies have reported reductions in HbA1c of up to 2.6 percentage points over around 40 to 52 weeks.
~25%
Weight reduction in one study
One published study of tirzepatide plus lifestyle changes reported around 25% weight reduction in a substantial participant group.
Individual results vary. Medication works best when used alongside dietary changes, movement and ongoing clinical support.
Available through NuVue
GLP-1 treatments currently available through NuVue
NuVue currently offers two GLP-1-based weight loss treatments: Mounjaro and Wegovy.
Mounjaro
Weekly injectionMounjaro contains tirzepatide and is often chosen by patients looking for a highly effective injectable option with strong appetite and weight loss support.
- Dual-action support affecting GLP-1 and GIP pathways
- May suit patients seeking stronger appetite control
- Used once weekly
Wegovy
Weekly injectionWegovy contains semaglutide and is a clinically established GLP-1 treatment that may help reduce hunger, support portion control and encourage steady weight loss.
- GLP-1-based appetite and fullness support
- May suit patients wanting a proven injectable option
- Used once weekly